In a news release, Revive Therapeutics Ltd. (RVV:TSX.V; RVVTF:OTCMKTS) announced it appointed John Fahy, MD, MSc, as a scientific and clinical adviser to help expand and analyze the data from the ongoing Phase 3 clinical trial evaluating Bucillamine as a treatment for patients with mild to moderate COVID-19.
"Dr. Fahy is a distinguished clinical researcher with thiol-based drugs, such as Bucillamine, and his understanding of its mechanism of action and how it relates to SARS-CoV-2 will be valuable in assessing our interim analysis of our U.S. Food and Drug Administration Phase 3 study," Revive CEO Michael Frank said in the release.
Fahy wrote the recently published article "Thiol-Based Drugs Decrease Binding of SARS-CoV-2 Spike Protein to its Receptor and Inhibit SARS-CoV-2 Cell Entry." He is a professor of medicine at the University of California, San Francisco's (UCSF's) Division of Pulmonary and Critical Care Medicine and holds the Michael S. Stulbarg Endowed Chair in Pulmonary Medicine there. Also, Fahy is the director of UCSF's Asthma Clinic and its Airway Clinical Research Center.
After obtaining a medical degree from the University College Dublin in Ireland, he completed a fellowship in pulmonary and critical care medicine at UCSF.
"Bucillamine, a cysteine derivative with two thiol groups, has been shown to be 16 times more potent as a thiol donor in vivo than N-acetyl-cysteine. Bucillamine has a well-known safety profile with over 30 years of use as a treatment for rheumatoid arthritis in Japan and South Korea," the company stated.
Read what other experts are saying about:
Disclosure:
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: Revive Therapeutics. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the decision to publish an article until three business days after the publication of the article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of Revive Therapeutics, a company mentioned in this article.
